Akari Therapeutics PLC ADR AKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKTX is a good fit for your portfolio.
News
-
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
-
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HRT, NX, AKTX
-
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
-
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
-
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
-
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
Trading Information
- Previous Close Price
- $3.99
- Day Range
- $3.86–4.40
- 52-Week Range
- $1.08–5.50
- Bid/Ask
- $4.01 / $4.28
- Market Cap
- $49.90 Mil
- Volume/Avg
- 24,610 / 27,049
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
- Website
- https://www.akaritx.com
Valuation
Metric
|
AKTX
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
AKTX
|
---|---|
Quick Ratio | 0.21 |
Current Ratio | 0.44 |
Interest Coverage | — |
Quick Ratio
AKTX
Profitability
Metric
|
AKTX
|
---|---|
Return on Assets (Normalized) | −337.83% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AKTX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Bvzdsztc | Dmpn | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Qlzgbhspj | Lybxmjn | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Zkxsfwv | Lcnvw | $118.7 Bil | |||
Moderna Inc
MRNA
| Bmmngdbpk | Gtl | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Cxykxkqf | Lwfcm | $29.7 Bil | |||
argenx SE ADR
ARGX
| Jjlwhxhsv | Hpsz | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Ttdlrrnvk | Mdxb | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Bswtgtfv | Gpyszdn | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Yvdpxdnf | Grrgv | $15.0 Bil | |||
Incyte Corp
INCY
| Xhfgxdbb | Nbjchfw | $13.5 Bil |